AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation.
The last earnings update was 40 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
AnaptysBio. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
AnaptysBio's earnings available for a low price, and how does
this compare to other companies in the same industry?
AnaptysBio is not considered high growth as it is expected to be loss making for the next 1-3 years.
AnaptysBio's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
AnaptysBio's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Hamza Suria, M.Sc., M.B.A. has been the Chief Executive Officer and President of AnaptysBio, Inc., since July 2011. Mr. Suria served as an Acting Chief Executive Officer and Chief Business Officer of AnaptysBio, Inc. He served as Vice President of Corporate Development at Anaptys Biosciences, Inc. since December 2008. He was appointed Vice President of Corporate Development in December 2008. He served as Senior Director of Business Development at Maxygen, where he was responsible for partnering and alliance management of next-generation protein therapeutics with Roche, Sanofi-Aventis, Bayer, Astellas and others. Mr. Suria served as Director of Business Development at Diabetogen Biosciences with responsibility for corporate partnerships with Abgenix and the development of otelixizumab. He held various business development positions at Viron Therapeutics and the Robarts Research Institute. He has been a Director of AnaptysBio, Inc. since July 2011. Mr. Suria holds a BSc in Biochemistry from Kalamazoo College, an MSc in Immunology from the University of Western Ontario and an Executive MBA from the Richard Ivey School of Business. Mr. Suria is an ASAP-certified Alliance Management Professional.
Hamza's compensation has increased whilst company is loss making.
Hamza's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the AnaptysBio management team is about average.
Chief Financial Officer
Chief Medical Officer
Senior Vice President of Manufacturing
VP & Controller
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the AnaptysBio board of directors is about average.
Is AnaptysBio, Inc. (NASDAQ:ANAB) A Financially Strong Company?
See our latest analysis for AnaptysBio ANAB’s Debt (And Cash Flows) Over the past year, ANAB has reduced its debt from US$13m to US$8.6m , which also accounts for long term debt. … Next Steps: Although ANAB’s debt level is relatively low, its cash flow levels still could not copiously cover its borrowings. … However, the company will be able to pay all of its upcoming liabilities from its current short-term assets.
Did You Manage To Avoid AnaptysBio's (NASDAQ:ANAB) 42% Share Price Drop?
AnaptysBio isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … Shareholders of unprofitable companies usually expect strong revenue growth. … In just one year AnaptysBio saw its revenue fall by 50%.
Is AnaptysBio Inc (NASDAQ:ANAB) As Strong As Its Balance Sheet Indicates?
Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like AnaptysBio Inc (NASDAQ:ANAB), with a market cap of US$2.2b, are often out of the spotlight. … This article will examine ANAB’s financial liquidity and debt levels to get an idea of whether the company can deal with cyclical downturns and maintain funds to accommodate strategic spending for future growth. … Don’t forget that this is a general and concentrated examination of AnaptysBio's financial health, so you should conduct further analysis.
Market Sentiment Around Loss-Making AnaptysBio Inc (NASDAQ:ANAB)
The company’s loss has recently broadened since it announced a -US$30.07m loss in the full financial year, compared to the latest trailing-twelve-month loss of -US$33.72m, moving it further away from breakeven? … The most pressing concern for investors is ANAB’s path to profitability – when will it breakeven
What You Must Know About AnaptysBio Inc's (NASDAQ:ANAB) Financial Health
View our latest analysis for AnaptysBio How does ANAB’s operating cash flow stack up against its debt? … At this current level of debt, ANAB's cash and short-term investments stands at US$248.41M for investing into the business. … Moving onto cash from operations, its small level of operating cash flow means calculating cash-to-debt wouldn't be too useful, though these low levels of cash means that operational efficiency is worth a look.
There's room for improvement on the cash management side of things, but its overall debt level and interest coverage somewhat increases my conviction of the sustainability of the business going forward. … One reason I do like ANAB as a business is its low level of fixed assets on its balance sheet (0.20% of total assets). … A good company is reflected in its financials, and for ANAB, the financials don't look good.
Future Outlook Of The Healthcare Industry And AnaptysBio Inc (ANAB)
The growth in development of new drugs for unmet needs, as well as the ongoing and increasing need for biotech drugs as Baby Boomer generation continues to age, are growth drivers for the positive outlook in the biotech industry over the long term. … Healthcare analysts are forecasting for the entire industry, negative growth in the upcoming year , and a massive growth of 44.94% over the next couple of years. … Over the past year, the industry saw growth of 8.45%, though still underperforming the wider US stock market.
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company’s products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases. It is also developing immuno-oncology products, including TSR-042: anti-PD-1, TSR-022: anti-TIM-3, TSR-033: anti-LAG-3, and TSR-075: anti-PD-1/LAG-3 bispecific; and CC-90006: anti-PD-1 agonist for psoriasis, as well as other products for inflammation. AnaptysBio, Inc. has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Ltd., including an anti-PD-1 antagonist antibody (TSR-042), an anti-TIM-3 antagonist antibody (TSR-022), and an anti-LAG-3 antagonist antibody (TSR-033); and an inflammation partnership with Celgene Corporation, including an anti-PD-1 checkpoint agonist antibody (CC-90006) in clinical development. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is headquartered in San Diego, California.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.